Peficitinib治疗MTX应答不足的日本类风湿关节炎患者的III期随机双盲安慰剂对照试验(RAJ4)
这项多中心、双盲、平行组、安慰剂对照III期研究纳入519例对甲氨蝶呤应答不足的日本类风湿关节炎患者,随机接受安慰剂、peficitinib 100 mg每日一次或150 mg每日一次联合MTX治疗52周。结果显示,peficitinib组第12周/提前终止时ACR20应答率显著高于安慰剂组,第28周/提前终止时mTSS较基线变化显著低于安慰剂组。Peficitinib伴有血液学和生化参数变化,严重感染和带状疱疹相关疾病发生率增加。
要点
- Peficitinib 100 mg和150 mg组ACR20应答率分别为58.6%和64.4%,显著高于安慰剂组的21.8%(p<0.001)。
- Peficitinib 100 mg和150 mg组第28周mTSS较基线平均变化分别为1.62和1.03,显著低于安慰剂组的3.37(p<0.001)。
- Peficitinib伴有血液学和生化参数变化,严重感染和带状疱疹相关疾病发生率增加。
核心结论
- 在对MTX应答不足的日本RA患者中,peficitinib在减轻RA症状和抑制关节破坏方面显著优于安慰剂。
- Peficitinib具有可接受的安全性和耐受性特征,与其他JAK抑制剂相比未发现新的安全性信号。
研究设计与样本
- 多中心、双盲、平行组、安慰剂对照III期研究,纳入对MTX应答不足的RA患者,随机1:1:1接受安慰剂、peficitinib 100 mg每日一次或150 mg每日一次联合MTX治疗52周,共519例患者随机并接受治疗。
- 第12周时安慰剂组无应答者根据基线随机化转为peficitinib直至治疗结束,其余患者在28周时转为peficitinib。
主要发现
- 第12周/提前终止时,peficitinib 100 mg组ACR20应答率为58.6%,150 mg组为64.4%,安慰剂组为21.8%,差异显著(p<0.001)。
- 第28周/提前终止时,peficitinib 100 mg组mTSS较基线平均变化为1.62,150 mg组为1.03,安慰剂组为3.37,差异显著(p<0.001)。
- Peficitinib伴有血液学和生化参数变化,严重感染和带状疱疹相关疾病发生率增加。
- 安慰剂组一名患者在转为peficitinib 100 mg后发生一例自杀死亡。
关键数值与推荐
- 主要疗效指标为第12周/提前终止时ACR20应答率,以及第28周/提前终止时van der Heijde改良总Sharp评分(mTSS)较基线的变化。
临床怎么用
- 对于对MTX应答不足的RA患者,peficitinib联合MTX可显著提高ACR20应答率并抑制关节破坏进展。
- 使用peficitinib时应监测血液学和生化参数,并警惕严重感染和带状疱疹相关疾病的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of the oral Janus kinase (JAK) inhibitor peficitinib versus placebo in Japanese patients with rheumatoid arthritis (RA). METHODS: In this multicentre, double-blind, parallel-group, placebo-controlled phase III study, patients with RA and inadequate response to methotrexate (MTX) were randomised 1:1:1 to placebo, peficitinib 100 mg once daily or peficitinib 150 mg once daily with MTX for 52 weeks. Based on baseline randomisation, at week 12, non-responders receiving placebo were switched to peficitinib until the end of treatment; the remaining patients were switched to peficitinib at week 28. Primary efficacy variables were American College of Rheumatology (ACR)20 response rate at week 12/early termination (ET) and change from baseline in van der Heijde-modified total Sharp score (mTSS) at week 28/ET. RESULTS: 519 patients were randomised and treated. Significantly more (p<0.001) peficitinib (58.6%, 100 mg; 64.4%, 150 mg) than placebo (21.8%) recipients achieved ACR20 response at week 12/ET. Significantly lower (p<0.001) mean changes from baseline in mTSS at week 28/ET occurred in peficitinib (1.62, 100 mg; 1.03, 150 mg) than placebo (3.37) recipients. Peficitinib was associated with haematological and biochemical parameter changes, and increased incidence of serious infections and herpes zoster-related disease. One death from suicide occurred in a patient in the placebo group after switching to peficitinib 100 mg. CONCLUSIONS: In Japanese patients with RA and inadequate response to MTX, peficitinib demonstrated significant superiority versus placebo in reducing RA symptoms and suppressing joint destruction. Peficitinib had an acceptable safety and tolerability profile, with no new safety signals compared with other JAK inhibitors. TRIAL REGISTRATION NUMBER: NCT02305849.
引用
- Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019. PMID: 31350269. doi:10.1136/annrheumdis-2019-215164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。